Stockholm, 18 June 2026 — Modus Therapeutics Holding AB (publ) (Nasdaq First North Growth Market: MODTX) announces that Professor Kathryn Maitland and her research group at Imperial College London have submitted a manuscript based on the Phase Ib study SEVUSMART for publication in the journal Nature Communications. The manuscript is available as a preprint via Research Square.
SEVUSMART is a Phase Ib study evaluating sevuparin as an adjunctive treatment for severe malaria in children. The study is conducted as an investigator-led study with Imperial College London as sponsor and Professor Maitland as principal investigator, funded by a research grant from the Wellcome Trust. Modus Therapeutics contributed sevuparin as well as scientific and regulatory expertise, and holds the commercial rights to the drug candidate.
“The submission of the SEVUSMART manuscript is an important step in the ongoing work to document sevuparin’s clinical profile in severe malaria. Pending peer review, we can note that the study has clearly defined the dose for the next study and confirms sevuparin’s favorable safety and tolerability profile,” says John Öhd, CEO of Modus Therapeutics. “We welcome Professor Maitland’s research group sharing their findings with the scientific community and look forward to the continued work to identify the next steps in program development.”
The manuscript posted on Research Square can be found here: Sevuparin in children with severe malaria: A phase I safety and dose finding trial | Research Square
About SEVUSMART
SEVUSMART (ISRCTN number: ISRCTN32271864) is a Phase Ib study evaluating the dosing and tolerability/safety of sevuparin in combination with standard of care for severe malaria in up to 20 pediatric patients aged 3 months to 12 years. The study was conducted at research centers in Kenya and Zambia and completed patient recruitment in March 2025. Imperial College London is the sponsor; the study has been funded by the Wellcome Trust.